electroCore vs Neuraxis
ECOR and NRXS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ECOR and NRXS compare
Neuraxis is the larger company, worth 1.3 times as much as electroCore ($57.9M against $43.2M).
electroCore scores higher on the StockData Score (7 against 0 for Neuraxis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ECOR | NRXS |
|---|---|---|
| Size and price | ||
| Market cap | $43.2M | $57.9M |
| Share price | $4.79 | $4.61 |
| Change, 1 year | −14.5% | 97.0% |
| Change, 5 years | −58.0% | – |
| Beta (5Y) | 2.38 | 0.67 |
| Employees | 83 | 24 |
| StockData Score | ||
| Total score | 7 (better) | 0 |
| Valuation score | 1 (better) | 0 |
| Growth score | 4 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.2× | – |
| FCF yield | −22.6% | – |
| Growth | ||
| Revenue growth (TTM) | 33.5% | – |
| Revenue growth, 5Y average | 55.7% | – |
| Profitability | ||
| Gross margin | 87.1% | – |
| Operating margin | −37.6% | – |
| Net margin | −40.0% | – |
| FCF margin | −26.4% | – |
| Financial health | ||
| Interest coverage | −1095.5× | – |
| Current ratio | 1.21 | – |
| Altman Z-score | −15.41 | – |
| Piotroski F-score | 3 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 11.4% | 21.7% |
| Held by insiders | 16.7% | 39.9% |
| Insider net buying, 12 months | −$667K | $1.4M (better) |
| Short interest, % of float | 4.8% | 6.0% |
Go deeper
- ECOR stock overview
- ECOR income statement
- ECOR valuation and score
- NRXS stock overview
- NRXS income statement
- NRXS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.